Effect of progestational agents on gonadal and adrenal cortical function in patients with benign prostatic hypertrophy and carcinoma of the prostate.
D015068:17-Ketosteroids / Q000652:urine; D000311:Adrenal Glands / Q000187:drug effects / Q000503:physiopathology*; D000818:Animals; D002277:Carcinoma / Q000503:physiopathology; D002715:Chlormadinone Acetate / Q000494:pharmacology*; D004967:Estrogens / Q000652:urine; D006065:Gonadotropins, Pituitary / Q000652:urine; D006066:Gonads / Q000187:drug effects / Q000503:physiopathology*; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000652:urine; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D013739:Testosterone / Q000097:blood
D015068:17-Ketosteroids; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D006908:Hydroxyprogesterones; D002715:Chlormadinone Acetate; D013739:Testosterone; D007986:Luteinizing Hormone